Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Acute Myeloid Leukemia: early-phase trial registry
36 of 64 indexed Refractory Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 36 currently recruiting · #215 of 28,707 conditions by registered trial count
Refractory Acute Myeloid Leukemia: 64 US clinical trials tracked, 36 recruiting.
Refractory Acute Myeloid Leukemia is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 36 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 20 of these trials.
Enrollment posture brief
Registry condition refractory-acute-myeloid-leukemia
OPEN 36 | RECR 56% | LATE 0 | EARLY 64 | RANK #215 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Alcohol Intoxication (56% recruiting · 16 trials)
Refractory Acute Myeloid Leukemia lists 36 open slots (56% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Acute Myeloid Leukemia is recruiting above its size-band peers.
36 of 64 indexed trials (56.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Acute Myeloid Leukemia research.
M.D. Anderson Cancer Center accounts for 20 of 64 trials (31.3%). 23 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 64 trials that report a genuine target (sentinel values excluded). 58 of those (90.6%) plan for fewer than 100 participants.
-
Refractory Acute Myeloid Leukemia research is mostly interventional.
64 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 1 of 2
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT06501196
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
NCT04375631
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02392572
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03214562
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT04140487
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03471260
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04774393
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04047641
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT03128034
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03661307
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
NCT04797767
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT06399640
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
NCT03969446
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT06484062
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04128748
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03629171
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Jennifer Saultz
NCT03874052
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
NCT03683433
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
NCT03816319
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05010122
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT06928662
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05263284
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03670966
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04493164
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Uma Borate
NCT06222580
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
NCT04049539
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05672147
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT06871410
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
NCT05627232
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT06177067
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
NCT06561152
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
CERo Therapeutics Holdings
NCT06834282
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Terrence J Bradley, MD
NCT05597306
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT06017258
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT07025564
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT06763341
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics
NCT04891757
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04746235
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03247088
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT03041688
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT02890329
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03672539
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT03983824
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT03513484
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT04898894
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
NCT03132454
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
City of Hope Medical Center
NCT03009240
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03289910
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04975919
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT04188405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 12 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Acute Myeloid Leukemia page
64 registered trials, 36 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 36 Refractory Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Refractory Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Acute Myeloid Leukemia condition card totals 64 registered trials; most-linked intervention Venetoclax; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.